Affordable Access

Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center.

Authors
  • Jain, Ashokkumar B
  • Marcos, Amadeo
  • Pokharna, Renu
  • Shapiro, Ron
  • Fontes, Paulo A
  • Marsh, Wallace
  • Mohanka, Ravi
  • Fung, John J
Type
Published Article
Journal
Transplantation Journal
Publisher
Ovid Technologies (Wolters Kluwer) - Lippincott Williams & Wilkins
Publication Date
Dec 27, 2005
Volume
80
Issue
12
Pages
1692–1698
Identifiers
PMID: 16378063
Source
Medline
License
Unknown

Abstract

Sixty percent (3 of 5) of patients who received rituximab as primary therapy had complete resolution, and 44% (4 of 9) of patients who received it as rescue therapy had partial response. Overall 5-year patient survival was a disappointing 35%.

Report this publication

Statistics

Seen <100 times